Novel targeted therapies for Parkinson's disease

Parkinson's disease (PD) is the second more common neurodegenerative disease with increasing incidence worldwide associated to the population ageing. Despite increasing awareness and significant research advancements, treatment options comprise dopamine repleting, symptomatic therapies that hav...

Full description

Saved in:
Bibliographic Details
Published in:Molecular medicine (Cambridge, Mass.) Mass.), 2021-02, Vol.27 (1), p.17-17, Article 17
Main Authors: Ntetsika, Theodora, Papathoma, Paraskevi-Evita, Markaki, Ioanna
Format: Article
Language:English
Subjects:
Biomarkers
Clinical trials
Dopamine
Drug development
Enzymes
Gene expression
Gene therapy
Genomes
Medical imaging
Medicin och hälsovetenskap
Mutagenesis
Nervous system
Neurons
Parkinson's disease
Quality of life
Review
Therapeutics
Vectors (Biology)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson's disease (PD) is the second more common neurodegenerative disease with increasing incidence worldwide associated to the population ageing. Despite increasing awareness and significant research advancements, treatment options comprise dopamine repleting, symptomatic therapies that have significantly increased quality of life and life expectancy, but no therapies that halt or reverse disease progression, which remain a great, unmet goal in PD research. Large biomarker development programs are undertaken to identify disease signatures that will improve patient selection and outcome measures in clinical trials. In this review, we summarize PD-related mechanisms that can serve as targets of therapeutic interventions aiming to slow or modify disease progression, as well as previous and ongoing clinical trials in each field, and discuss future perspectives.
ISSN:1076-1551
1528-3658
1528-3658
DOI:10.1186/s10020-021-00279-2